Paper · 40358804
Epidemiology of WHO grade 2 and grade 3 gliomas from 2009 to 2021 in Germany.
Weidl D and 8 others. J Neurooncol, 2025. Cited by 3 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Epidemiology of WHO grade 2 and grade 3 gliomas from 2009 to 2021 in Germany. Papers, record 40358804. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40358804
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glioma | Major topic |
| Brain Neoplasms | Major topic |
| Humans | |
| Germany | |
| Neoplasm Grading | |
| Male | |
| Female | |
| Mutation | |
| Middle Aged | |
| Registries | |
| Adult | |
| Isocitrate Dehydrogenase | |
| Aged | |
| World Health Organization | |
| Incidence | |
| Young Adult | |
| Adolescent | |
| Child |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37,603,235 | Long-term follow up of patients with WHO grade 2 oligodendroglioma. | J Neurooncol | 2023 | https://conductscience.org/library/papers/37603235 | PubMed |
| 2 | 27,888,628 | Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system. | Oncotarget | 2017 | https://conductscience.org/library/papers/27888628 | PubMed |
| 3 | 31,621,043 | Observation after surgery for low grade glioma: long-term outcome in the light of the 2016 WHO classification. | J Neurooncol | 2019 | https://conductscience.org/library/papers/31621043 | PubMed |
| 4 | 37,477,610 | What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib? | Neuro Oncol | 2023 | https://conductscience.org/library/papers/37477610 | PubMed |
| 5 | 30,467,813 | Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system. | J Neurooncol | 2019 | https://conductscience.org/library/papers/30467813 | PubMed |
| 6 | 33,123,732 | CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. | Neuro Oncol | 2020 | https://conductscience.org/library/papers/33123732 | PubMed |
| 7 | 41,458,936 | Presenting clinical and radiographic features of diffuse glioma molecular subtypes in accordance with the 2021 CNS5 WHO classification. | Neurooncol Pract | 2025 | https://conductscience.org/library/papers/41458936 | PubMed |
| 8 | 30,529,899 | Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning. | Eur J Cancer | 2019 | https://conductscience.org/library/papers/30529899 | PubMed |
| 9 | 35,804,940 | Survival Outcomes and Prognostic Factors in Glioblastoma. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35804940 | PubMed |
| 10 | 24,842,956 | The epidemiology of glioma in adults: a "state of the science" review. | Neuro Oncol | 2014 | https://conductscience.org/library/papers/24842956 | PubMed |
1 to 10 of 25
See all 25 referencesCited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,652,791 | IDH-Mutant Diffuse Glioma: From Metabolic Origins to Targeted Therapy. | J Clin Med | 2026 | https://conductscience.org/library/papers/42652791 | PubMed |
| 42,474,656 | Regulatory delay and lost opportunity in IDH-mutant low-grade glioma. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42474656 | PubMed |
| 42,287,505 | Patient Preferences and Treatment Decision Drivers in IDH-Mutant Grade 2 Glioma: An International Discrete Choice Experiment. | Patient | 2026 | https://conductscience.org/library/papers/42287505 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IDH1 | 3,417 | PubTator's text mining | https://conductscience.org/library/genes/3417 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40358804
GET https://conductscience.org/api/papers/v1/40358804/references?page=2